Sanofi has entered into an agreement to acquire Blueprint Medicines Corp., a U.S.-based biopharma company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, for a total transaction valued at approximately $9.5 billion. The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the U.S. and the EU, and a promising advanced and early-stage immunology pipeline. Blueprint also brings an established ...